By a vote of 274 to 131, US House of Representatives passed legislation (the American Research and Competitiveness Act; HR 4438), which increase and make permanent the R&D tax credit. HR 4438 would increase the tax credit to 20% from the 14% credit which expired last year. The bill will now go to the US Senate.
Congressional budget analysts estimate the government would lose about $156 billion in revenue over 10 years under the House bill (HR 4438), which does not include any offsets to recover the tax credit’s cost.
However, although the House bill has bipartisan support, the White House is threatening a veto. The Senate, meanwhile, is working on its own bill, which would extend the R&D tax break for just two years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze